NOVARTIS for NOVARTIS
What was lobbied
9 issue areas, each in the filer's own words, with who lobbied on it and where.
Budget/Appropriations BUD
Advanced Research Projects Agency for Health (ARPA-H) Biosimilars Drug Pricing Fiscal year 2023 Appropriations H.R. 6833 - Continuing Appropriations H.R.1, For the People Act of 2021 H.R.1319, American Rescue Plan Act of 2021 H.R.2471, Consolidated Appropriations Act for FY 2022 H.R.5376, Inflation Reduction Act Importation National Defense Authorization Act FY 2023 Prescription Drug User Fee Act (PDUFA) VII Value of Medicine
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TAYLOR BOOTH | — |
| NORA CONNORS | — |
| LEO A FARBER | — |
| SARAH HALLER | — |
| COURTNEY LEE-ASHLEY | — |
| JOSEPH MCGOWAN | — |
| SHELLY MUI-LIPNIK | — |
| SEEMIN PASHA | — |
| COURTNEY PIRON | — |
Copyright/Patent/Trademark CPT
Antitrust Legislation Bayh-Dole Act Biopharmaceutical Intellectual Property Biosimilars BPCIA Compulsory licenses Data Exclusivity Intellectual Property Issues in Response to coronavirus Inter Parties Review at PTO Patent Litigation Reform and Issues Related to Post Grant Proceedings at PTO Patents S.1435, Affordable Prescriptions for Patients Act of 2021 S.225, Competition and Antitrust Law Enforcement Reform Act Section 101 H.R. 2883, the Stop Stalling Access to Affordable Medications H.R. 2891, the Preserve Access to Affordable Generics and Biosimilars Act H.R. 2873, the Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 H.R. 2884, the Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act WTO TRIPS Waiver H.R. 5376 - Inflation Reduction Act
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TAYLOR BOOTH | — |
| NORA CONNORS | — |
| LEO A FARBER | — |
| SARAH HALLER | — |
| COURTNEY LEE-ASHLEY | — |
| JOSEPH MCGOWAN | — |
| SEEMIN PASHA | — |
| COURTNEY PIRON | — |
Health Issues HCR
21st Century Cures Act 2.0 340B Drug Discount Program Advanced Research Projects Agency for Health (ARPA-H) Biosimilar approval and reimbursement policy issues BLOCKING Act Buy American and other associated issues related to procurement and sourcing of finished product and active pharmaceutical ingredients Cell, gene and radioligand therapies Co-pay accumulator programs COVID-19 Diversity in Clinical Trials Drug cost and pricing policy issues Drug Importation and counterfeiting policy issues Drug shortages policy issues Drug vial size policy issues FDA modernization policy issues Foreign manufacturing policy issues FY 2023 Appropriations H.R.2471, Consolidated Appropriations Act for FY 2022 H.R.2815, The BIOSIM Act H.R. 4390 - Protect 340B Act of 2021 H.R.3, Elijah E. Cummings Lower Drug Costs Now Act H.R.5463, Drug Pricing Transparency and Accountability Act H.R. 5260, Reduced Costs and Continued Cures Act H.R. 4811, Medicare Negotiation and Competitive Licensing Act of 2021 Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020 Medicaid Generics Penalty Fix Medicaid Payment Reform H.R. 5376 - Inflation Reduction Act H.R. 5801 - HELP Co-pays Act H.R. 7389 - MVP Act H.R. 6584 - DEPICT Act Notice of Benefit Payment Parameters (NBPP) Orphan Drugs Outcomes based contracting/value based arrangements Part B Home Infusion Patient assistance program policy issues PDUFA, BSUFA, GDUFA H.R 7667 - Food and Drug Amendments Act of 2022 S.4348 - FDASLA Act of 2022 Pharmaceutical quality Pharmaceutical supply chain H.R.5388/S.2740 PREPARE ACT of 2021 (API stockpiling) Priority Review Voucher (PRV) Regulatory efficiencies policy issues S.1427, HR 2869 - Increasing Access to Biosimilars Act of 2021 Transparency policy issues Vaccines White House National Biodefense Strategy H.R. 5416, The Give Kids a Chance Act S. 2837 - 340B Accountability Act 2021 Pharmacy benefit manager policy issues Cancer Moonshot
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TAYLOR BOOTH | — |
| NORA CONNORS | — |
| LEO A FARBER | — |
| SARAH HALLER | — |
| COURTNEY LEE-ASHLEY | — |
| JOSEPH MCGOWAN | — |
| SHELLY MUI-LIPNIK | — |
| SEEMIN PASHA | — |
| COURTNEY PIRON | — |
Medicare/Medicaid MMM
Anti-Kickback Statute policy issues ASP reporting policy issues Center for Medicare and Medicaid Innovation (CMMI) policy issues Drug Pricing Drug wastage rebates policy issues Innovative Pharmaceuticals (including cell, gene and radioligand therapies), Biosimilars and Generics Medicaid Medicare Part D Negotiations Medicare Part D Re-design and out of pocket cap Medicaid rebates and waiver policy issues Medicare Part A, B and D Outcomes based Contracting/value based arrangements Patient Cost-Sharing and Smoothing Reimbursement for cell therapy products Removal of Safe Harbor Protection for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals Transparency policy issues
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TAYLOR BOOTH | — |
| NORA CONNORS | — |
| LEO A FARBER | — |
| COURTNEY LEE-ASHLEY | — |
| JOSEPH MCGOWAN | — |
| SEEMIN PASHA | — |
| COURTNEY PIRON | — |
Science/Technology SCI
Artificial intelligence Data and digital technologies
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LEO A FARBER | — |
| SARAH HALLER | — |
| SHELLY MUI-LIPNIK | — |
| COURTNEY PIRON | — |
Taxation/Internal Revenue Code TAX
ACA Pharmacetuical Industry Fee Administration's FY 2022 Revenue Proposals Base Erosion Anti-Abuse Tax (BEAT) OECD Digital Tax Orphan Drug Tax Pharmaceutical supply chain incentives R&D Amortization Restrict deductions of excessive interest of members of financial reporting groups for disproportionate borrowing in the United States (Sec. 163(n) & 163(o)) Stopping Harmful Inversions and Ending Low-Tax Developments (SHIELD) Tax Treaties Thin Capitalization Rules 163(j) U.S. Corporate Tax
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TAYLOR BOOTH | — |
| NORA CONNORS | — |
| LEO A FARBER | — |
| SARAH HALLER | — |
| JOSEPH MCGOWAN | — |
| SHELLY MUI-LIPNIK | — |
| SEEMIN PASHA | — |
| COURTNEY PIRON | — |
Trade (domestic/foreign) TRD
Access to Medicines Issues Biopharmaceutical Innovation Policies US China Agreement US Swiss Trade Relations US Switzerland Mutual Recognition Agreement on GMP Free Trade Agreements - Intellectual Property and Transparency Provisions Global Health Issues India, China and Canada IP and Market Access Issues Intellectual property International Market Access and Intellectual Property Issues Pharmaceutical Supply Chain Pricing and reimbursement policy issues Quality of Medicines Regulatory Cooperation Supply chain and China Task Force policy issues Tariffs Trade Policy WTO IP Waiver
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TAYLOR BOOTH | — |
| NORA CONNORS | — |
| LEO A FARBER | — |
| SARAH HALLER | — |
| COURTNEY LEE-ASHLEY | — |
| JOSEPH MCGOWAN | — |
| SHELLY MUI-LIPNIK | — |
| SEEMIN PASHA | — |
| COURTNEY PIRON | — |
Veterans VET
Health care collaboration opportunities
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LEO A FARBER | — |
| JOSEPH MCGOWAN | — |
| COURTNEY PIRON | — |
Labor Issues/Antitrust/Workplace LBR
Anti-Trust Reform The Competition and Antitrust Law Enforcement Reform Act (S.225)
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LEO A FARBER | — |
| JOSEPH MCGOWAN | — |
| SHELLY MUI-LIPNIK | — |
| COURTNEY PIRON | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.